-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $3

Benzinga·11/16/2026 12:56:27
Listen to the news
Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $7 to $3.